CYP2C19 rs17222419: Understanding Your Genetic Metabolism
The rs17222419 variant is located within the CYP2C19 gene, which provides instructions for making an enzyme responsible for processing various medications. This specific genetic variation is associated with altered enzyme activity, which can influence how an individual's body metabolizes drugs like clopidogrel and certain proton pump inhibitors.
What each genotype means
Normal enzyme activity
This genotype is typically associated with normal CYP2C19 enzyme function, often referred to as the extensive metabolizer phenotype. Individuals with this profile generally process medications like clopidogrel and certain proton pump inhibitors at standard rates. Please discuss any medication dosing or concerns with your clinician or pharmacist.
This is the most common genotype globally, though frequencies vary significantly by ancestry.
Reduced enzyme activity
This genotype indicates the presence of one non-functional allele, which may lead to reduced CYP2C19 enzyme activity compared to those with two functional copies. This can affect how your body metabolizes specific drugs, potentially requiring adjustments to medication therapy. Please consult your healthcare provider or pharmacist to discuss how this may influence your treatment plan.
This heterozygous genotype is found in a significant portion of the global population, with higher prevalence in many ethnic groups.
Poor enzyme activity
This genotype is associated with poor metabolism of certain medications, such as clopidogrel, because the CYP2C19 enzyme activity is significantly reduced or absent. Being a poor metabolizer may impact the effectiveness of these drugs, as the body cannot convert them into their active forms efficiently. It is important to discuss this result with your clinician or pharmacist to determine if alternative therapies or dose adjustments are appropriate for you.
This genotype is observed in approximately 2% of White and 4% of Black populations, with higher frequencies reported in Asian populations.
What is the rs17222419 Variant?
The rs17222419 variant is a single nucleotide polymorphism (SNP) found within the CYP2C19 gene, located on chromosome 10. In the context of pharmacogenomics, researchers study such variants to understand why individuals respond differently to the same dose of a medication. This specific variant is often categorized as a non-functional or reduced-function allele, meaning it may lead to the production of an enzyme that does not work as efficiently as the standard version. When an individual carries this variant, the metabolic pathway for specific drugs may be slowed, potentially leading to higher or lower concentrations of the drug in the bloodstream than intended. Because the CYP2C19 gene is highly polymorphic, meaning it has many different variations, rs17222419 is one of several markers used by clinicians to help predict how a patient might process specific therapeutic compounds.
The Role of the CYP2C19 Gene
The CYP2C19 gene encodes a member of the cytochrome P450 superfamily of enzymes. These enzymes are primarily found in the liver and are essential for the metabolism of a wide range of substances, including toxins and pharmaceutical drugs. For many medications, such as the antiplatelet drug clopidogrel, the CYP2C19 enzyme acts as a 'bioactivator.' This means the drug is administered as an inactive prodrug and must be converted by the enzyme into its active form to provide the desired therapeutic effect. If the CYP2C19 enzyme is not functioning optimally due to genetic variants like rs17222419, the conversion process is impaired. This can result in reduced clinical efficacy for the patient. Understanding the function of this gene is a cornerstone of precision medicine, as it allows healthcare providers to tailor treatment plans based on an individual's unique genetic profile.
Research and Clinical Associations
Scientific research has established a strong link between CYP2C19 variants and the metabolism of clopidogrel. Clinical guidelines, such as those provided by the Clinical Pharmacogenetics Implementation Consortium (CPIC), emphasize that patients identified as intermediate or poor metabolizers may experience reduced platelet inhibition when taking clopidogrel. This is a significant clinical concern, as it may increase the risk of adverse cardiovascular or cerebrovascular events. While the evidence for these associations is robust, it is important to note that genetic status is only one factor in drug response. Other variables, including age, diet, drug-drug interactions, and underlying health conditions, also play critical roles. The evidence strength for these associations is considered moderate to high in clinical settings, leading many professional organizations to recommend genotype-guided therapy for patients starting certain medications.
Population Frequency and Variability
The frequency of CYP2C19 variants varies significantly across different ancestral populations. While the rs17222419 variant and other non-functional alleles are present globally, their prevalence is not uniform. For instance, certain loss-of-function alleles are more common in Asian populations compared to European or African populations. This global diversity means that the likelihood of carrying a specific genotype depends heavily on an individual's genetic ancestry. Current data suggests that these variants appear in approximately 15-25% of the global population, though this range fluctuates based on the specific population being studied. Because of this variability, genetic testing results should always be interpreted within the context of an individual's broader clinical picture and ancestral background, rather than in isolation.
Navigating Your Genetic Information
If you have received information about your CYP2C19 genotype, it is essential to understand what you can and cannot do with this data. This information is a tool for your healthcare provider, not a diagnostic result in itself. You should never change your medication dosage or stop taking a prescribed drug based on genetic test results without consulting your doctor or pharmacist. Genetic testing provides a piece of the puzzle, but your clinician must integrate this with your medical history, current symptoms, and other laboratory tests to make safe, informed decisions. If you are concerned about how your body processes a specific medication, bring your genetic report to your next appointment. Your healthcare provider can explain how these findings apply to your specific treatment plan and whether an alternative therapy or dosage adjustment is appropriate for your needs.
How common is this variant?
The rs17222419 variant and related CYP2C19 non-functional alleles are found in approximately 15-25% of the global population, with significant frequency differences observed across diverse ancestral groups.
Frequently asked questions
Does having this variant mean I cannot take clopidogrel?
Not necessarily. Having a variant that affects metabolism does not mean you cannot take a medication, but it may mean your doctor needs to adjust your dose or choose an alternative therapy to ensure the drug is effective for you.
Is this genetic test a diagnosis?
No, a genetic test for a SNP is not a medical diagnosis. It is a piece of information that helps your doctor understand how your body might process certain medications, which is just one factor in your overall health.
Should I change my medication if I have this variant?
You should never change or stop your medication based on genetic test results without speaking to your doctor. Only a healthcare professional can determine if your current treatment plan is appropriate for your specific genetic profile.
Where can I find more information on CYP2C19 guidelines?
You can find authoritative information on pharmacogenetic guidelines through the Clinical Pharmacogenetics Implementation Consortium (CPIC) website or the PharmGKB database. These resources provide evidence-based recommendations for clinicians.
Sources & further reading
Educational information only, last refreshed 10/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs17222419?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C19
Defines the CYP2C19*17 increased function allele, conferring rapid or ultrarapid metabolism for CPIC-actionable drugs including clopidogrel, PPIs, and SSRIs.
The CYP2C19*2 loss-of-function splicing defect results in impaired biotransformation of prodrugs including clopidogrel and altered clearance of proton pump inhibitors and select antidepressants.
Variant in the CYP2C19 locus associated with altered metabolism of clopidogrel and proton-pump inhibitors.
Defines the CYP2C19*8 loss-of-function variant (c.358T>C, p.Trp120Arg) which results in no enzymatic activity and impaired metabolism of CYP2C19 substrates.
Defines the non-functional CYP2C19*3 null allele resulting from a premature stop codon, leading to poor metabolism of drugs such as clopidogrel, escitalopram, and proton pump inhibitors.
Defines the CYP2C19*4 allele caused by an ATG start codon alteration that abolishes translation, resulting in reduced or absent drug metabolism capacity.